Dihydroartemisinin induces autophagy and inhibits the growth of iron-loaded human myeloid leukemia K562 cells via ROS toxicity

FEBS Open Bio

Volumn 2, Issue , 2012, Pages 103-112

  Wang, Zeng ^a,b   Hu, Wei ^a   Zhang, Jia Li ^a   Wu, Xiu Hua ^a   Zhou, Hui Jun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Dihydroartemisinin; Iron; K562 cell; Mitophagy; ROS

Indexed keywords

CASPASE 3; DIHYDROARTEMISININ; IRON; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; TRANSFERRIN RECEPTOR;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN K 562; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON OVERLOAD; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

EID: 84861830311     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2012.05.002     Document Type: Article

References (37)

1. Meshnick S.R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 2002, 32:1655-1660.
2. Disbrow G., Baege A., Kierpiec K., Yuan H., Centeno J., Thibodeaux C., Hartmann D., Schlegel R. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res. 2005, 5:10854-10861.
3. David S., Tiphanie P., Cindy L., Susan E. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 2002, 179:151-156.
4. Efferth T., Dunstan H., Sauerbrey A., Miyachi H., Chitambar C. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 2001, 18:767-773.
5. Moore J., Lai H., Li J.R., Ren R.L., McDougall J.A., Singh N.P., Chou C.K. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett. 1995, 98:83-87.
6. Lai H., Singh N.P. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 2001, 70:49-56.
7. Lai H., Sasaki T., Singh N.P., Messay A. Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci. 2005, 76:1267-1279.
8. Huang W.P., Klionsky D.J. Autophagy in yeast: a review of the molecular machinery. Cell Struct. Funct. 2002, 27:409-420.
9. Noda T., Suzuki K., Ohsumi Y. Yeast autophagosomes: de novo formation of a membrane structure. Trends Cell Biol. 2002, 12:231-235.
10. Ohsumi Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nat. Rev. Mol. Cell Biol. 2001, 2:211-216.
11. Zhou D., Spector S.A. Human immunodeficiency virus type-1 infection inhibits autophagy. AIDS 2008, 22:695-699.
12. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., Rubinsztein D.C. Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003, 278:25009-25013.
13. Ravikumar B., Duden R., Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 2002, 11:1107-1117.
14. Komatsu M., Kominami E., Tanaka K. Autophagy and neuro-degeneration. Autophagy 2006, 2:315-317.
15. Crighton D., Wilkinson S., O'Prey J., Syed N., Harrison P.R., Gasco M., Garrone O., Crook T., Ryan K.M. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 14:121-134.
16. Takeda K., Yoshida T., Kikuchi S., Nagao K., Kokubu A., et al. Synergistic roles of the proteasome and autophagy for mitochondrial maintenance and chronological lifespan in fission yeast. Proc. Natl. Acad. Sci. USA 2010, 107:3540-3545.
17. Lemasters J.J. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res. 2005, 8:3-5.
18. Kim I., Rodriguez-Enriquez S., Lemasters J.J. Selective degradation of mitochondria by mitophagy. Arch. Biochem. Biophys. 2007, 462:245-253.
19. Okamoto K., Kondo-Okamoto N., Ohsumi Y. Mitochondria-anchored receptor Atg32 mediates degradation of mitochondria via selective autophagy. Dev. Cell 2009, 17:87-97.
20. Kwok J.C., Richardson D.R. The iron metabolism of neoplastic cells: alterations that facilitate proliferation?. Crit. Rev. Oncol. Hematol. 2002, 42:65-78.
21. Peng J.L., Wu S., Zhao X.P., Wang M., Li W.H., Shen X., Liu J., Lei P., Zhu H.F., Shen G.X. Downregulation of transferrin receptor surface expression by intracellular antibody. Biochem. Biophys. Res. Commun. 2007, 354:864-871.
22. Neckers L.M., Trepel J.B. Transferrin receptor expression and the control of cell growth. Cancer Invest. 1986, 4:461-470.
23. Callens C., Moura I.C., Lepelletier Y., Coulon S., Renand A., Dussiot M., Ghez D., Benhamou M., Monteiro R.C., Bazarbachi A., Hermine1 O. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia 2008, 22:42-48.
24. Fukuchi K., Tomoyasu S., Tsuruoka N., Gomi K. Iron deprivation induced apoptosis in HL-60 cell. FEBS Lett. 1994, 350:139-142.
25. Kovár J., Valenta T., Ehrlichová M., Polák J., Naumann P.W. Iron deprivation induces apoptosis independently of p53 in human and murine tumour cells. Cell Prolif. 2003, 36:199-213.
26. Thornberry Nancy A., Lazebnik Y. Caspases: enemies within. Science 1998, 281:1312-1316.
27. Karen M.H., John J.T. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res. 1999, 59:3077-3083.
28. Lauricella M., Emanuele S., D'Anneo A., Calvaruso G., Vassallo B., Carlisi D., Portanova P., Vento R., Tesoriere G. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis 2006, 11:607-625.
29. Reddy C.M., Bhat V.B., Kiranmai G., Reddy M.N., Reddanna P., Madyastha K.M. Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis. Biochem. Biophys. Res. Commun. 2000, 277:599-603.
30. Federica S., Yohan S.R., Egarit N., Des R.R. Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1α and p53. Mol. Pharmacol. 2010, 77:443-458.
31. Zhou H.J., Wang Z., Li A. Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression. Anticancer Drugs 2008, 19:247-255.
32. Galluzzi L., Aaronson S.A., Abrams J., Alnemri E.S., Andrews D.W., Baehrecke E.H., Bazan N.G., Blagosklonny M.V., et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 2009, 16:1093-1107.
33. Levine B., Yuan J. Autophagy in cell death: an innocent convict?. J. Clin. Invest. 2005, 115:2679-2688.
34. Levine B. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell 2005, 120:159-162.
35. Efferth T., Benakis A., Romero M.R., Tomicic M., Rauh R., Steinbach D., Hafer R., Stamminger T., Oesch F., Kaina B., Marschall M. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med. 2004, 37:998-1009.
36. Tracy R.D., Tracie D., Jose A.R. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 2006, 121:144-158.
37. Kelter G., Steinbach D., Konkimalla V.B., Tahara T., Taketani S., Fiebig H.H., Efferth T. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS ONE 2007, 2:e798.